Sonnet BioTherapeutics (SONN) Competitors $3.54 -0.22 (-5.85%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$3.50 -0.04 (-1.13%) As of 08/15/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SONN vs. CALC, ENLV, SNYR, PLUR, STTK, XLO, PEPG, EQ, ALXO, and AKTXShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include CalciMedica (CALC), Enlivex Therapeutics (ENLV), Synergy CHC (SNYR), Pluri (PLUR), Shattuck Labs (STTK), Xilio Therapeutics (XLO), PepGen (PEPG), Equillium (EQ), ALX Oncology (ALXO), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Its Competitors CalciMedica Enlivex Therapeutics Synergy CHC Pluri Shattuck Labs Xilio Therapeutics PepGen Equillium ALX Oncology Akari Therapeutics Sonnet BioTherapeutics (NASDAQ:SONN) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings. Which has better earnings and valuation, SONN or CALC? Sonnet BioTherapeutics has higher revenue and earnings than CalciMedica. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonnet BioTherapeutics$20K561.09-$7.44MN/AN/ACalciMedicaN/AN/A-$13.70M-$1.60-1.82 Which has more volatility & risk, SONN or CALC? Sonnet BioTherapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Does the media prefer SONN or CALC? In the previous week, CalciMedica had 4 more articles in the media than Sonnet BioTherapeutics. MarketBeat recorded 9 mentions for CalciMedica and 5 mentions for Sonnet BioTherapeutics. CalciMedica's average media sentiment score of 0.21 beat Sonnet BioTherapeutics' score of -0.14 indicating that CalciMedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonnet BioTherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of SONN or CALC? 9.5% of Sonnet BioTherapeutics shares are held by institutional investors. 2.0% of Sonnet BioTherapeutics shares are held by insiders. Comparatively, 41.5% of CalciMedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate SONN or CALC? Sonnet BioTherapeutics currently has a consensus price target of $20.00, indicating a potential upside of 464.97%. CalciMedica has a consensus price target of $16.00, indicating a potential upside of 449.83%. Given Sonnet BioTherapeutics' higher possible upside, research analysts plainly believe Sonnet BioTherapeutics is more favorable than CalciMedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00CalciMedica 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SONN or CALC more profitable? CalciMedica's return on equity of -206.51% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sonnet BioTherapeuticsN/A -4,646.10% -342.21% CalciMedica N/A -206.51%-103.81% SummaryCalciMedica beats Sonnet BioTherapeutics on 6 of the 10 factors compared between the two stocks. Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.90M$3.10B$5.68B$9.81BDividend YieldN/A2.23%3.79%4.11%P/E RatioN/A20.8931.0825.11Price / Sales561.09364.47466.21115.16Price / CashN/A42.3037.4059.05Price / Book-3.698.659.096.18Net Income-$7.44M-$54.65M$3.26B$265.11M7 Day Performance9.94%6.56%7.36%4.21%1 Month Performance-58.89%7.53%5.47%2.01%1 Year Performance-32.70%13.69%30.61%23.74% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics2.9144 of 5 stars$3.54-5.9%$20.00+465.0%-45.4%$11.90M$20K0.0010Earnings ReportAnalyst UpgradeGap DownCALCCalciMedica3.3664 of 5 stars$2.50-9.5%$16.00+540.8%-29.0%$35.40MN/A-1.6230Earnings ReportShort Interest ↓Analyst RevisionGap UpENLVEnlivex Therapeutics3.3415 of 5 stars$1.51+2.7%$10.00+562.3%+49.2%$35.36MN/A-2.2770News CoverageShort Interest ↓Gap UpSNYRSynergy CHC4.3959 of 5 stars$3.84+8.5%$10.00+160.4%N/A$35.29M$34.83M0.0040News CoverageEarnings ReportAnalyst RevisionPLURPluri2.252 of 5 stars$4.47-7.3%$12.00+168.5%-13.9%$35.18M$330K-0.81150Short Interest ↑STTKShattuck Labs3.6977 of 5 stars$0.72-2.9%$7.50+944.6%-69.6%$35.06M$5.72M-0.53100News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpXLOXilio Therapeutics2.8171 of 5 stars$0.67+1.5%$3.00+345.8%-14.6%$35.00M$6.34M-0.8070News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionHigh Trading VolumePEPGPepGen3.194 of 5 stars$1.06-1.4%$7.67+626.7%-85.8%$33.95MN/A-0.3530Gap UpEQEquillium2.8217 of 5 stars$0.92+4.0%$3.00+225.7%+40.8%$33.72M$41.10M-2.4240Earnings ReportShort Interest ↓Gap UpALXOALX Oncology2.9095 of 5 stars$0.62+0.2%$3.30+435.7%-75.7%$33.64MN/A-0.2640Earnings ReportGap DownAKTXAkari Therapeutics3.1104 of 5 stars$1.01-3.4%$5.00+393.1%-68.4%$33.63MN/A0.009Upcoming EarningsGap Up Related Companies and Tools Related Companies CalciMedica Competitors Enlivex Therapeutics Competitors Synergy CHC Competitors Pluri Competitors Shattuck Labs Competitors Xilio Therapeutics Competitors PepGen Competitors Equillium Competitors ALX Oncology Competitors Akari Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SONN) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access